6:33 PM
 | 
Dec 17, 2012
 |  BC Extra  |  Company News

IQWiG: 'no additional benefit' for epilepsy drug Fycompa

Germany's Institute for Quality and Efficiency in Health Care (IQWiG) said epilepsy drug Fycompa perampanel from Eisai Co. Ltd. (Tokyo:4523; Osaka:4523) provides "no additional benefit" over comparators requested by Germany's Federal Joint Committee (G-BA). G-BA requested lamotrigine as a...

Read the full 189 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >